Scientific Advisory Board
Scientific Advisory Board
Leadership
Leadership
Daekwon Kim / CEO, R&D
Korea Health Industry Development Institute
Seoul National University, Pharmacy, M.S.
Seoul National University, Pharmacy, B.S.
Hyuntai Kim / CEO, Management
Seoul National University Business School, MBA
Seoul National University Business School, B.A.
Younkyoung Lee / Clinical Development
Boehringer Ingelheim Korea, Clinical Development Director
Seoul National University, Public Health, M.S.
Seoul National University, Nursing, B.S.
Dr. Sunghwan Kim / Biochemistry
Polus, Development Director
Catholic University, Research Professor
Massachusetts Institute of Technology(MIT), Post Doc
Sangjin Woo / Finance
Seoul National University Business School, MBA
Seoul National University Business School, B.A.
Ikhwan Sung / Operations
McKinsey & Co. / The Rohatyn Group
Wharton School, MBA
Seoul National University Business School, B.A.
Sangjin Lee / Human Resources
Bank of Korea
Seoul National University, Economics, B.A.
Jaeyoung Ahn / Business Development(Advanced markets)
UC Berkeley, MFE
Seoul National University, Engineering, B.S.
Junil Park / Business Development(China and Emerging markets)
Mirae Asset, PEF
Peking University, B.A.
Giho Kwon / Legal Affairs
46th Judicial Examination
Seoul National University, Law, LL.M.
Seoul National University, Law, LL.B.
Noori Seo / External Relations
Sungkyunkwan University Law School, LL.M.
Seoul National University, Politics, B.A.
Lim Jaeyoung / Intellectual Property
Patent attorney
KIM&CHANG
Seoul National University, B.S.
Hyunseok Kim / Artificial Intelligence
Hongik University, Adjunct Professor
Yonsei University, Engineering, M.S.
Dr.Namdoo Kim / CEO of Voronoi Bio
National New Drug Development Center
Yonsei University, Ph.D.
Dr. Jungbeom Son / CTO of Voronoi Bio
Sogang University, Ph.D.
Dr. Hwangeun Choi / CEO of B2S Bio
“Small-Molecule Inhibitors of LRRK2”(2017), Advances in Neurobiology vol. 14, Co-author
Dana Farber Cancer Institute, Staff Scientist
Dr. Nathanael Gray / Co-Founder of B2S Bio
Professor at Harvard Medical School(Dana Farber Cancer Institute)
Genomics Institute of the Novartis Research Foundation Kinase Inhibitor Group Leader
Dr. Eunhwa Ko / CTO of B2S Bio
Yale University, Post Doc
Texas A&M University, Ph.D.